Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.58 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 8/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005115 | 0.84 | HPGD (0.48) | FASNPADI4HPGDMAPK1KMT2A | |
| SCHEMBL22004148 | 0.77 | KMT2A (0.54) | FASNHPGDKMT2ACYP19A1TSHR | |
| SCHEMBL17404507 | 0.74 | FASN (1.00) | FASN | |
| SCHEMBL25145101 | 0.73 | PADI4 (0.61) | FASNPADI4HPGDKMT2AALDH1A1 | |
| SCHEMBL11749917 | 0.71 | CYP19A1 (0.58) | FASNHPGDKMT2ACYP19A1TSHR | |
| SCHEMBL30547738 | 0.71 | HPGD (0.58) | HPGDKMT2ATSHRPOLBMAPT | |
| SCHEMBL2614250 | 0.71 | TSHR (0.71) | HPGDMAPK1KMT2AGHSRTSHR | |
| SCHEMBL5332167 | 0.71 | KMT2A (0.60) | FASNHPGDKMT2ACYP19A1ACLY | |
| SCHEMBL31400972 | 0.70 | ACLY (0.51) | FASNKMT2ACYP19A1TSHRACLY | |
| SCHEMBL3381195 | 0.70 | ACLY (0.51) | FASNKMT2ACYP19A1TSHRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | FASN 552/4885PADI4 945/4885HPGD 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.